The Ministry of Industry and Information Technology (MIIT), together with nine other departments, formulated and issued the “15th Five‑Year Plan for Pharmaceutical Industry Development” (the “Plan”), setting quantitative industry targets and deploying 25 key tasks across eight priority areas to steer China’s pharmaceutical sector toward innovation‑driven, high‑quality growth.
Policy Snapshot
| Item | Detail |
|---|---|
| Issuing Authorities | MIIT and nine other departments |
| Policy | “15th Five‑Year Plan for Pharmaceutical Industry Development” |
| Coverage Period | 15th Five‑Year Plan period (2026–2030) |
| Structure | Expected development indicators + 25 key tasks in eight areas |
| Issuance Date | 18 Sep 2026 |
Expected Development Indicators
| Dimension | Target Indicator |
|---|---|
| Industrial Scale & Efficiency | Operating revenue of pharmaceutical industrial enterprises above designated size exceeding RMB 3.5 trillion; annual average growth rate of the innovative drug industry scale over 20 %; more than 5 products with global annual sales exceeding US$1 billion |
| Innovation Breakthroughs | Average R&D investment intensity of listed pharmaceutical industrial enterprises over 10 % annually; number of new drug pipelines entering first‑time clinical trials and innovative drugs approved for marketing ranking among the world’s forefront; share of first‑in‑class (FIC) drugs in the global total over 25 %; more than 200 innovative medical devices approved for marketing |
| Enterprise & Cluster Development | 50 pharmaceutical industrial enterprises with annual operating revenue exceeding RMB 10 billion; 20 hundred‑billion‑yuan pharmaceutical industrial parks |
Eight Key Task Areas
- Innovation‑Driven Growth: Lead the industry toward new and superior development – enhance original innovation capabilities, fully leverage industrial innovation platforms, actively cultivate and strengthen the innovative pharmaceutical and medical device industry, and accelerate the layout of cutting‑edge technologies and products.
- Resilient & Secure Supply System: Strengthen foundations and leverage advantages – consolidate the industrial foundation and competitive advantages, and cultivate new drivers of development.
- Digital‑Intelligent Transformation: Set new benchmarks for quality and efficiency – deepen AI‑enabled upgrading, promote digital‑intelligent transformation, and accelerate green upgrading.
- Precision Diagnosis & Treatment: Cultivate new paradigms adapting to technological evolution – develop precision prevention pharmaceutical and device products, expand the precision diagnostics industry scale, and build a precision treatment industry ecosystem.
- Efficient Industrial Ecosystem: Smooth the channel for efficient clinical translation, improve the system for engineering scale‑up, and create a pattern of efficient industrial collaboration.
- Value Creation Expansion: Promote coordinated improvement of quantity and quality – deepen the health value of the pharmaceutical industry, enhance its social value, and cultivate its cultural value.
- Supply Guarantee & Drug Access: Build a new cornerstone for inclusive health – improve the diversified guarantee system, strengthen quality supply of essential drugs and medical devices, and continuously improve drug accessibility.
- International Cooperation: Deepen international industrial cooperation – enhance industrial competitiveness, elevate the level of industrial cooperation, and increase market attractiveness.
Market Impact & Outlook
- Innovation Premium: With over 20 % annual growth targeted for the innovative drug sector and a 25 %+ global share goal for first‑in‑class drugs, the Plan elevates FIC innovation from corporate strategy to national industrial policy – favoring R&D‑intensive biotechs and pharma groups with differentiated pipelines.
- Consolidation Signal: The targets of 50 ten‑billion‑yuan enterprises and 20 hundred‑billion‑yuan parks point to accelerated industry consolidation and cluster formation, with scale advantages concentrating around leading hubs and platforms.
- AI & Digitalization Tailwind: Explicit emphasis on AI‑enabled upgrading and digital‑intelligent transformation creates policy support for AI drug discovery, smart manufacturing, and digital quality systems across the value chain.
- Device Sector Boost: A target of more than 200 innovative medical devices approved for marketing signals sustained regulatory and industrial support for high‑end device innovation alongside pharmaceuticals.
- Global Integration: The openness agenda – elevating international industrial cooperation and market attractiveness – aligns with the industry’s outward push via licensing, globalization of clinical trials, and cross‑border partnerships.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the implementation of the “15th Five‑Year Plan for Pharmaceutical Industry Development,” including industrial growth rates, innovation targets, enterprise cultivation, and international cooperation outcomes. Actual results may differ materially due to risks including policy implementation timelines, market conditions, technological evolution, regulatory changes, and global trade dynamics.-Fineline Info & Tech
